Kidney cancer, characterized by the uncontrolled growth of malignant cells in the kidneys, is a significant global health challenge, with an estimated 400,000 new cases annually and nearly 175,000 deaths per year. The disease is commonly treated with first-line therapies, including immune checkpoint inhibitors and targeted therapies. However, a high unmet clinical need for more effective treatments remains, as current options often result in limited patient outcomes. The growing focus on immunotherapies, targeted treatments, and combination therapies is expected to drive the development of promising pipeline drugs, offering hope for improved survival rates and quality of life for patients in the future.
The Advanced Kidney Cancer Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into advanced kidney cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for advanced kidney cancer. The advanced kidney cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The advanced kidney cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with advanced kidney cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to advanced kidney cancer.
Advanced kidney cancer occurs when cancer cells grow uncontrollably in the kidneys, often spreading to other organs. It typically presents as clear-cell renal cell carcinoma (ccRCC), the most common form. Factors like smoking, obesity, and hypertension increase the risk of developing advanced kidney cancer. Early-stage cancers are treatable, but advanced stages are harder to manage, creating a significant clinical need for new therapies.
Advanced kidney cancer is primarily treated with targeted therapies, including tyrosine kinase inhibitors, and immune checkpoint inhibitors like nivolumab and pembrolizumab. Combination treatments, such as immunotherapy combined with targeted agents, are also increasingly used. These therapies aim to slow tumor growth and improve patient survival, addressing the significant unmet need for more effective treatment options in advanced stages.
The advanced kidney cancer drug pipeline is crucial in addressing the increasing incidence of renal cell carcinoma, which affects approximately 9 individuals per 100,000 people annually in Spain. In the United States, approximately 81,800 new cases and 14,890 deaths from renal cell carcinoma and other kidney tumors were estimated in 2023. About 50% of cases are localized, while 25% are diagnosed with advanced or regional kidney cancer.
This section of the report covers the analysis of advanced kidney cancer drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total advanced kidney cancer clinical trials.
The drug molecule categories covered under the advanced kidney cancer pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for advanced kidney cancer.
The EMR report for the advanced kidney cancer report insights includes the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in advanced kidney cancer clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for advanced kidney cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of advanced kidney cancer drug candidates.
The study, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., aims to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in patients with advanced renal cancer. This Phase 3 trial involves 528 participants and is expected to be completed by June 2025, with primary completion projected for December 2025.
The Phase II clinical trial sponsored by Emory University evaluates neoadjuvant cabozantinib for treating patients with locally advanced non-metastatic clear cell renal cell carcinoma before surgery. The primary objective is to assess the objective response rate following 12 weeks of treatment. The study is expected to be completed by February 2025 and has enrolled 22 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Advanced Kidney Cancer Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for advanced kidney cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within advanced kidney cancer pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share